# Long Term Safety and Efficacy of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Perennial Allergic Rhinitis (PAR)

> **NCT02709538** · PHASE3 · COMPLETED · sponsor: **Glenmark Specialty S.A.** · enrollment: 601 (actual)

## Conditions studied

- Perennial Allergic Rhinitis

## Interventions

- **DRUG:** GSP 301 NS
- **DRUG:** GSP 301 Placebo NS pH 3.7
- **DRUG:** GSP 301 Placebo NS pH 7.0

## Key facts

- **NCT ID:** NCT02709538
- **Lead sponsor:** Glenmark Specialty S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2017-07
- **Final completion:** 2017-07
- **Target enrollment:** 601 (ACTUAL)
- **Last updated:** 2020-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02709538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02709538, "Long Term Safety and Efficacy of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Perennial Allergic Rhinitis (PAR)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02709538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*